To study the impact of NKG2D and CD33 engagement on the cytolytic activity of CC-96191 against human CD33+ AML cell lines, we generated variants of CC-96191 in which either the NKG2D binding arm or the CD33 binding arm were replaced with irrelevant binding domains. This evidence concerns the gene CD33 and acute myeloid leukemia.